Lapatinib Tablets: Essential Guide To Dosage & Side Effects
Comprehensive guide to Lapatinib (Tyverb) for HER2-positive advanced breast cancer treatment, dosage, side effects, and patient advice.
Lapatinib (Tyverb) is a targeted oral medication specifically designed for treating advanced or metastatic breast cancer that overexpresses the HER2 protein in patients who have already undergone prior therapies like anthracyclines, taxanes, and trastuzumab.
This tyrosine kinase inhibitor works by blocking the activity of HER2 and EGFR proteins, which are crucial for cancer cell growth and proliferation. Approved by the FDA in 2007 and used under brand names Tykerb in the US and Tyverb elsewhere, it is typically combined with capecitabine or an aromatase inhibitor like letrozole for optimal efficacy.
About Lapatinib Tablets
Lapatinib is an antineoplastic agent classified as a small-molecule tyrosine kinase inhibitor. It targets the intracellular tyrosine kinase domains of both epidermal growth factor receptor (EGFR/HER1) and human epidermal growth factor receptor 2 (HER2/ERBB2). By competitively binding to the ATP-binding site, lapatinib prevents receptor autophosphorylation and downstream signaling pathways like MAPK and PI3K/Akt, leading to growth arrest or apoptosis in tumor cells.
Developed by GlaxoSmithKline (now Novartis in some regions), lapatinib was approved for use in combination with capecitabine for HER2-positive metastatic breast cancer (MBC) after prior treatments failed. It also received approval for use with letrozole in hormone receptor-positive, HER2-positive postmenopausal MBC.
In clinical studies, lapatinib demonstrated additive effects with capecitabine’s active metabolite (5-fluorouracil) in vitro and retained activity against trastuzumab-resistant cell lines, suggesting no cross-resistance.
Before Taking Lapatinib
Consult your doctor if you have any allergies to lapatinib or its components. Inform your healthcare provider about your full medical history, especially heart conditions, lung issues, or liver problems, as lapatinib can affect left ventricular ejection fraction (LVEF) and cause interstitial lung disease.
Lapatinib may interact with numerous medications, including CYP3A4 inhibitors (e.g., ketoconazole), inducers (e.g., rifampin), and substrates (e.g., midazolam). Grapefruit and related products should be avoided due to CYP3A4 inhibition. It also affects digoxin, paclitaxel, and hormonal contraceptives, potentially reducing their efficacy.
- Pregnancy and Breastfeeding: Lapatinib can harm the fetus; effective contraception is required during treatment and for at least 1 week after. Do not breastfeed during treatment and for 1 week post-discontinuation.
- Driving and Operating Machinery: Dizziness or fatigue may occur; avoid if affected.
- Food Interactions: Take on an empty stomach (1 hour before or 2 hours after meals) to avoid increased exposure.
How to Take Lapatinib
Lapatinib tablets are taken orally once daily. Swallow whole with water; do not chew, crush, or divide. The standard regimen for HER2-positive MBC with capecitabine is 1,250 mg (5 tablets of 250 mg) daily on days 1-21, combined with capecitabine 2,000 mg/m² daily on days 1-14 of a 21-day cycle.
For hormone receptor-positive HER2-positive MBC with letrozole, the dose is 1,500 mg (6 tablets) daily continuously with letrozole 2.5 mg daily.
| Indication | Lapatinib Dose | Combination | Schedule |
|---|---|---|---|
| HER2+ MBC (post prior therapy) | 1,250 mg once daily | Capecitabine 2,000 mg/m²/day | Days 1-21 continuous; capecitabine days 1-14 |
| HR+ HER2+ postmenopausal MBC | 1,500 mg once daily | Letrozole 2.5 mg daily | Continuous |
Do not divide the daily dose. If a dose is missed, skip it and resume the next day; do not double dose. Dose adjustments may be needed for toxicity: reduce by 250 mg increments to a minimum of 500 mg.
Common Questions About Lapatinib
How does lapatinib work?
Lapatinib inhibits the kinase activity of HER1/EGFR and HER2, preventing signal transduction that promotes cancer cell survival and proliferation. This dual inhibition is particularly effective in HER2-overexpressing tumors.
Who can take it?
Patients with advanced or metastatic HER2-positive breast cancer who have progressed on prior anthracycline, taxane, and trastuzumab therapy. Also for HR+ HER2+ cases in combination with aromatase inhibitors.
How long is treatment?
Treatment continues indefinitely until disease progression or unacceptable toxicity. Regular monitoring of LVEF and other parameters is essential.
Side Effects of Lapatinib
Most side effects are manageable, but some require immediate medical attention. Common ones include diarrhea (most frequent, up to 60%), rash, nausea, fatigue, and hand-foot syndrome (from capecitabine combo).
- Very Common (>10%): Diarrhea, nausea, rash, fatigue, hand-foot syndrome, vomiting, anorexia.
- Common (1-10%): Paronychia, dry skin, pruritus, alopecia, mucosal inflammation, headache, insomnia, dyspepsia, constipation, abdominal pain, hepatotoxicity (elevated liver enzymes).
- Serious (Rare): Decreased LVEF (monitor every 12 weeks), interstitial lung disease, severe diarrhea leading to dehydration, QT prolongation.
For diarrhea, use loperamide proactively; stay hydrated. Rash may require topical steroids. Interrupt treatment for severe toxicities and resume at lower dose upon recovery.
| Side Effect | Frequency | Management |
|---|---|---|
| Diarrhea | Very common | Loperamide; dose reduce if persistent |
| Rash | Very common | Moisturizers, topical steroids; antibiotics if infected |
| LVEF decrease | Common | Monitor echocardiograms; discontinue if >Grade 2 |
| Hepatotoxicity | Common | Liver function tests; interrupt if elevated |
Understanding Your Treatment
Lapatinib extends progression-free survival (PFS) in refractory HER2+ MBC. In trials, lapatinib + capecitabine improved time to progression vs. capecitabine alone (8.4 vs. 4.4 months). With letrozole, PFS was 8.2 vs. 3.0 months.
Treatment response varies; regular imaging and tumor markers guide continuation. It is not curative but controls disease.
Reporting Side Effects
Report serious side effects to your doctor immediately. In the US, use FDA MedWatch (1-800-FDA-1088); in the UK, Yellow Card scheme. Common issues like mild diarrhea can often be managed at home.
Further Support and Information
Discuss with your oncologist for personalized advice. Patient support groups and resources from organizations like Breast Cancer Now or American Cancer Society provide additional help.
Frequently Asked Questions (FAQs)
Q: Can lapatinib cure breast cancer?
A: No, lapatinib is not curative but helps control advanced or metastatic HER2-positive breast cancer by slowing progression.
Q: What if I miss a dose?
A: Skip the missed dose and take the next one as scheduled. Do not double up.
Q: Does lapatinib cause hair loss?
A: Mild alopecia is possible but less severe than with chemotherapy.
Q: How often is heart function monitored?
A: LVEF assessments at baseline, 12 weeks, then periodically, especially in the first year.
Q: Can I drink alcohol while taking lapatinib?
A: Limit alcohol as it may worsen side effects like diarrhea and liver strain. Consult your doctor.
References
- Lapatinib: Uses, Interactions, Mechanism of Action — DrugBank Online. 2023-10-15. https://go.drugbank.com/drugs/DB01259
- Lapatinib for Advanced or Metastatic Breast Cancer — PMC / National Library of Medicine. 2012-04-18. https://pmc.ncbi.nlm.nih.gov/articles/PMC3336826/
- Lapatinib (Tykerb): What to Expect, Side Effects — Breastcancer.org. 2024-05-20. https://www.breastcancer.org/treatment/targeted-therapy/tykerb
- Lapatinib (Tykerb®) — OncoLink / University of Pennsylvania. 2023-11-01. https://www.oncolink.org/cancer-treatment/oncolink-rx/lapatinib-tykerb-R
- Lapatinib (oral route) – Mayo Clinic — Mayo Clinic. 2024-02-10. https://www.mayoclinic.org/drugs-supplements/lapatinib-oral-route/description/drg-20070910
- Lapatinib (Tykerb): Uses & Side Effects — Cleveland Clinic. 2023-08-05. https://my.clevelandclinic.org/health/drugs/18067-lapatinib-oral-tablet
- TYKERB (lapatinib) tablets Prescribing Information — U.S. FDA. 2010-06-17. https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022059s007lbl.pdf
Similar Articles
Read full bio of Sneha Tete
